Shares of bluebird bio Inc (NASDAQ:BLUE) have earned a consensus rating of “Buy” from the twenty-five analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $170.78.

A number of equities research analysts have commented on the stock. Svb Leerink cut shares of bluebird bio from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Leerink Swann cut shares of bluebird bio from an “outperform” rating to a “market perform” rating and set a $150.00 price target for the company. in a report on Tuesday, March 5th. They noted that the move was a valuation call. ValuEngine upgraded shares of bluebird bio from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Cowen assumed coverage on shares of bluebird bio in a report on Tuesday, February 26th. They issued an “outperform” rating and a $149.91 price target for the company. Finally, SunTrust Banks reduced their price target on shares of bluebird bio to $184.00 and set a “buy” rating for the company in a report on Monday, February 25th.

NASDAQ:BLUE traded up $6.47 during trading hours on Friday, reaching $158.04. The company had a trading volume of 597,396 shares, compared to its average volume of 572,591. The stock has a market capitalization of $8.68 billion, a price-to-earnings ratio of -14.80 and a beta of 2.64. bluebird bio has a twelve month low of $87.49 and a twelve month high of $211.80.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) EPS for the quarter, topping analysts’ consensus estimates of ($2.83) by $0.11. The business had revenue of $19.20 million during the quarter, compared to analysts’ expectations of $9.06 million. bluebird bio had a negative net margin of 1,018.02% and a negative return on equity of 32.15%. The business’s quarterly revenue was up 357.1% on a year-over-year basis. During the same period last year, the company posted ($2.52) earnings per share. On average, research analysts forecast that bluebird bio will post -11.67 EPS for the current year.

In related news, insider David Davidson sold 7,600 shares of the business’s stock in a transaction dated Thursday, January 3rd. The shares were sold at an average price of $98.82, for a total transaction of $751,032.00. Following the transaction, the insider now directly owns 15,559 shares in the company, valued at $1,537,540.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Nick Leschly sold 7,374 shares of the business’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $113.64, for a total transaction of $837,981.36. Following the transaction, the insider now owns 20,682 shares in the company, valued at $2,350,302.48. The disclosure for this sale can be found here. Insiders have sold 42,826 shares of company stock valued at $5,526,727 over the last quarter. Corporate insiders own 3.00% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. NuWave Investment Management LLC boosted its holdings in bluebird bio by 14.4% during the fourth quarter. NuWave Investment Management LLC now owns 1,123 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 141 shares during the last quarter. Advisor Group Inc. raised its position in bluebird bio by 15.5% in the fourth quarter. Advisor Group Inc. now owns 1,256 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 169 shares during the period. Winslow Evans & Crocker Inc. raised its position in bluebird bio by 5.3% in the fourth quarter. Winslow Evans & Crocker Inc. now owns 4,000 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 200 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in bluebird bio by 7.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,353 shares of the biotechnology company’s stock worth $432,000 after acquiring an additional 286 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in bluebird bio by 36.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,104 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 296 shares during the period.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

See Also: 52-Week High/Low Prices For Stock Selection

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.